Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.

Anti-cancer drugs - 1 Sept 2018

Wang Ying, Liu Qiuyun, Chen Haojie, You Jun, Peng Bin, Cao Fanfan, Zhang Xue, Chen Qing, Uzan Georges, Xu Limin, Zhang Denghai

Abstract excerpt

The development of resistance to therapy continues to be a serious clinical problem in lung cancer management. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is one of the most common chemotherapy drugs to treat non-small-cell lung cancer. However, almost all treatments fail after ∼1 year of treatment because of drug tolerance, probably occurring from the threonine 790 mutation (T790M) of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Random Allocation

Share to Triterpenes

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 29927769
DOI: 10.1097/CAD.0000000000000647

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.PMID 29927769Read ↗

Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.Semantic proximity Read ↗

Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.Semantic proximity Read ↗

Monastrol Targeted KIF11 Showed Potential Treatment Effective of Small Cell Lung CancerSemantic proximity Read ↗

Effect of almonertinib on the proliferation, invasion, and migration in non-small cell lung cancer cells.Semantic proximity Read ↗

Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancerSemantic proximity Read ↗

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2.Semantic proximity Read ↗

Celastrol induces unfolded protein response-dependent cell death in head and neck cancerSemantic proximity Read ↗

Coccinic acid exhibits anti-tumor efficacy against NSCLC harboring EGFR L858R/T790M mutation via the EGFR/STAT3 pathway.Semantic proximity Read ↗

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations.Semantic proximity Read ↗

Simultaneous NF‐κB inhibition and E‐cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivoSemantic proximity Read ↗

miR-487b-5p Regulates Temozolomide Resistance of Lung Cancer Cells Through LAMP2-Medicated AutophagySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.